PlainPharmaWatch

CMS Open Payments · Tool

Noven Pharmaceuticals, Inc. vs HemoSonics LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

HemoSonics LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,152, versus 473 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Noven Pharmaceuticals, Inc.
HHI 473 · top recipient 0.1%
Ranked #1,308 of 1,838 companies by HHI
HemoSonics LLC
HHI 1,152 · top recipient 0.2%
Ranked #967 of 1,838 companies by HHI

Payment Overview

Total Payments
$337.1K
% of Industry
0.0%
Transactions
658
Avg per Transaction
$512.36
Recipients
658
Avg per Recipient
$512.36
Payment Types
4
Top Payment Type
Compensation for Faculty or Speaker (Medical Education)
Company B

HemoSonics LLC

Total Payments
$336.6K
% of Industry
0.0%
Transactions
237
Avg per Transaction
$1.4K
Recipients
219
Avg per Recipient
$1.5K
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

Noven Pharmaceuticals, Inc. vs HemoSonics LLC - total reported payments in CMS Open Payments PY2024

Noven Pharmaceuticals, Inc.$337.1KHemoSonics LLC$336.6K

Payment Types Breakdown

Noven Pharmaceuticals, Inc.

Compensation for Faculty or Speaker (Medical Education) $266.9K

79.2%

Food and Beverage $31.6K

9.4%

Travel and Lodging $24.7K

7.3%

Consulting Fee $13.9K

4.1%

HemoSonics LLC

Compensation for Services Other Than Consulting $37.1K

11.0%

Travel and Lodging $30.1K

8.9%

Consulting Fee $18.0K

5.3%

Food and Beverage $15.6K

4.6%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Noven Pharmaceuticals, Inc.

  1. 1

    MICHELLE HOLLOWAY

    $39,975.57 · 37 txns

  2. 2

    BIRGIT AMANN

    $29,277.92 · 24 txns

  3. 3

    GREGORY MATTINGLEY

    $21,678.13 · 16 txns

  4. 4

    NAPOLEON HIGGINS

    $20,020.37 · 19 txns

  5. 5

    ANDREW CUTLER

    $17,647.55 · 12 txns

HemoSonics LLC

  1. 1

    MELISSA ANNE BURGER

    $22,464.88 · 4 txns

  2. 2

    JONATHAN CHOW

    $15,281.74 · 5 txns

  3. 3

    ASAD SHAH

    $13,732.33 · 6 txns

  4. 4

    JOSEPH GRIGGS

    $12,374.87 · 7 txns

  5. 5

    DALLAS HACK

    $4,497.48 · 3 txns

Summary Comparison

Metric Noven Pharmaceuticals, Inc. HemoSonics LLC
Total Payments $337.1K $336.6K
% of Industry Total 0.0% 0.0%
Transaction Count 658 237
Avg per Transaction $512.36 $1.4K
Recipient Count 658 219
Avg per Recipient $512.36 $1.5K
Payment Type Count 4 4
Top Payment Type Compensation for Faculty or Speaker (Medical Education) Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.